Arbor Investment Advisors LLC Takes Position in Fresenius Medical Care AG (NYSE:FMS)

Arbor Investment Advisors LLC acquired a new stake in shares of Fresenius Medical Care AG (NYSE:FMS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 8,850 shares of the company’s stock, valued at approximately $200,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of FMS. Allworth Financial LP grew its holdings in shares of Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares in the last quarter. First Trust Direct Indexing L.P. grew its holdings in shares of Fresenius Medical Care by 9.7% in the third quarter. First Trust Direct Indexing L.P. now owns 22,901 shares of the company’s stock valued at $488,000 after purchasing an additional 2,021 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Fresenius Medical Care by 60.4% in the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after purchasing an additional 23,692 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after purchasing an additional 4,800 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Fresenius Medical Care in the third quarter valued at $420,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Up 0.6 %

NYSE FMS opened at $23.09 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The company has a fifty day moving average of $23.41 and a two-hundred day moving average of $21.68. The firm has a market capitalization of $13.55 billion, a price-to-earnings ratio of 19.08, a PEG ratio of 0.76 and a beta of 0.93. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $25.25.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on FMS shares. Truist Financial raised their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. StockNews.com raised shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Finally, Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.